# Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Source: https://onco.cc/trials/nct05944562/  
OnCo record `nct05944562` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of tulmimetostat in mycosis fungoides and Sezary syndrome, run by Washington University School of Medicine, active but no longer recruiting.

## Summary

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome is a phase 1 interventional study registered as NCT05944562 by Washington University School of Medicine, with Novartis, The Foundation for Barnes-Jewish Hospital, Swim Across America, Daniel E. Corbin Jr. Lymphoma Fund as collaborators; 24 participants are planned, it started on 2024-01-09; the registry gives 2027-02-28 as its primary completion date. Interventions recorded: Tulmimetostat. Conditions listed: Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05944562
- Phase: 1
- Setting: Phase I Study With an Expansion Cohort of Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
- Sponsor: Washington University School of Medicine
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT05944562: https://clinicaltrials.gov/study/NCT05944562

## Connected records

- cancers: [Mycosis fungoides](https://onco.cc/cancers/mycosis-fungoides/), [Sezary syndrome](https://onco.cc/cancers/sezary-syndrome/)
- drugs: [Tulmimetostat](https://onco.cc/drugs/tulmimetostat/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct05944562.json